Skip to main content
Holiday Sale — Get 40% off Vantage for yourself or as a gift
Get Started
SubscribeLogin
Published • loading... • Updated

Solengepras significantly reduces off time for patients on levodopa

Summary by Parkinson's News Today
Solengepras, an experimental oral therapy, reduced the number and duration of daily off episodes in Parkinson’s patients, Phase 2 data show.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

Parkinson's News TodayParkinson's News Today

Solengepras significantly reduces off time for patients on levodopa

Solengepras, an experimental oral therapy, reduced the number and duration of daily off episodes in Parkinson’s patients, Phase 2 data show.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Parkinson's News Today broke the news in on Friday, December 12, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Parkinson's Disease icon

Parkinson's Disease

Maryland icon

Maryland

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal